CellaVision AB (CEVI) AI Stock Analysis

• Market Cap: kr4.39B
• Dividend Yield: 1.37%
• Average Volume (3M): 25.00K
• Price to Earnings (P/E): 29.1
• Beta (1Y): 0.86
• Revenue Growth: 3.45%
• EPS Growth: 4.22%
• Country: SE
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.60
• Shares Outstanding: 23,851,547
• 10 Day Avg. Volume: 17,733
• 30 Day Avg. Volume: 24,999
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr196.85
• Price Target Upside: 8.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: kr197.00 ▲(8.24% Upside)

CellaVision AB's overall stock score is driven by its strong financial performance, characterized by robust revenue growth and profitability, and a stable balance sheet. Technical analysis indicates a potential upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call data and corporate events does not impact the score.

CellaVision AB Business Overview & Revenue Model

Company Description

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

How the Company Makes Money

CellaVision generates revenue through the sale of its digital microscopy systems, software licenses, and related services. The company's primary revenue streams include the initial sale of its diagnostic equipment, ongoing software subscriptions, and service agreements that ensure the maintenance and support of its products. Additionally, CellaVision benefits from partnerships with key players in the healthcare and diagnostic sectors, which help to expand its market reach and enhance its product offerings. The company also engages in continuous innovation, introducing new features and updates that can lead to increased sales and customer retention.

CellaVision AB Financial Statement Overview

Summary

CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion.

Income Statement

CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.

Cash Flow

CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	751.47M	723.22M	677.29M	639.34M	565.55M	471.44M
Gross Profit	517.24M	487.07M	463.04M	438.32M	392.30M	313.04M
EBITDA	230.90M	219.75M	207.25M	190.87M	193.60M	124.60M
Net Income	151.18M	140.72M	130.31M	118.33M	125.34M	89.48M
Balance Sheet
Total Assets	1.05B	1.01B	928.71M	891.75M	825.21M	668.02M
Cash, Cash Equivalents and Short-Term Investments	155.28M	149.43M	121.64M	108.05M	130.29M	102.26M
Total Debt	30.16M	26.85M	64.70M	102.50M	136.65M	132.78M
Total Liabilities	223.83M	196.16M	212.32M	250.12M	281.93M	238.41M
Stockholders Equity	822.94M	815.73M	716.39M	641.63M	543.28M	429.62M
Cash Flow
Free Cash Flow	78.50M	120.69M	109.96M	67.85M	75.41M	37.47M
Operating Cash Flow	206.35M	198.44M	196.44M	137.28M	159.72M	71.12M
Investing Cash Flow	-86.19M	-76.01M	-85.53M	-70.01M	-84.34M	-34.96M
Financing Cash Flow	-86.80M	-95.09M	-97.04M	-90.41M	-48.48M	-35.22M

CellaVision AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 182.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Positive. The current price of 182 is above the 20-day moving average (MA) of 177.67, above the 50-day MA of 173.26, and below the 200-day MA of 183.60, indicating a neutral trend. The MACD of 1.38 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 86.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CEVI.

CellaVision AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	71 Outperform	kr4.39B	29.06	18.65%	1.37%	3.45%	4.22%
CRAD.B	62 Neutral	kr1.10B	43.12	7.87%	―	-10.34%	-59.69%
XVIVO	57 Neutral	kr5.52B	47.77	5.17%	―	17.78%	-7.83%
BICO	54 Neutral	$1.52B	―	-15.03%	―	-21.56%	70.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	€1.24B	―	-5.40%	―	16.27%	-22.61%
SEZI	43 Neutral	$935.43M	―	-35.36%	―	71.41%	17.26%

CellaVision AB Corporate Events

CellaVision Appoints Monica Jönsson as Interim CFO

CellaVision has appointed Monica Jönsson as the Interim CFO, succeeding Magnus Blixt. Monica brings extensive experience from her previous roles, including her position as Group CFO at Perstorp Group. The company is in the process of recruiting a permanent CFO. This leadership change is expected to bring valuable expertise to CellaVision, potentially impacting its operations and market positioning positively.

The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK201.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.

CellaVision Reports Robust Q2 2025 Performance Amid Regional Variations

CellaVision’s Q2 2025 report shows a robust performance with a 7.6% organic sales growth despite mixed regional results. The APAC region saw significant growth due to increased shipments to China, while the Americas and EMEA experienced moderate growth. The company is advancing strategic priorities, including clinical trials for bone marrow analysis and software upgrades, and maintains a strong financial position. The departure of CFO Magnus Blixt marks a significant leadership change.

CellaVision to Release Q2 2025 Financial Report and Host Webcast

CellaVision AB announced it will release its second-quarter 2025 financial report on July 18, 2025, and will host a conference call and webcast for analysts, investors, and media. This event, led by CEO Simon Østergaard, will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perspectives on CellaVision’s market position and growth trajectory.